Skip to main content

Table 2 Prognostic value of chemotherapy-associated lymphopenia <0.66 × 10 9 /L for DFS of colorectal cancer

From: The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer

Variables Hazard ratio 95% confidence intervals P-value
Pretreatment albumin    
≥35 g/L 1.00(ref.)   
<35 g/L 1.000 0. 592–1. 692 0.999
Pretreatment CEA a    
<10 ng ml-1 1.00(ref.)   
≥10 ng ml-1 1. 827 1.040-3.211 0.036
Differentiation    
Well 1.00(ref.)   
Moderately 0. 676 0. 292–1.567 0.361
Low 0.882 0.294-2.644 0.823
Sex    
Male 1.00(ref.)   
Female 1.018 0.616-1.682 0.946
Age    
≤49 years 1.00(ref.)   
50-60 yeas 1.612 0.750-3.465 0.222
>60 years 1.386 0.673-2.854 0.376
Location    
Rectum 1.00(ref.)   
Left colon cancer 0.873 0.483-1.576 0.651
Right colon cancer 0.850 0.438-1.649 0.630
Stage    
II 1.00(ref.)   
III 2.723 1.549-4.786 0.001
Duration of lymphopenia <1.0 × 10 9L    
≤28 days 1.00(ref.)   
> 28 days 0.556 0.243-1.273 0.165
Chemotherapy-associated lymphocyte counts    
Lymphocyte counts ≥ 0.66 × 109/L 1.00(ref.)   
Lymphopenia <0.66 × 109/L 3.521 1.703-7.282 0.001
  1. a Carcinoembryonic antigen.